TABLE 3.
Bedside imaging test results
| COVID‐19 | Alternative diagnosis | Sensitivity % (95% CI) | Specificity % (95% CI) | AUC % (95% CI) | ||
|---|---|---|---|---|---|---|
| LUS | 464 (%) | 146 (%) | 318 (%) | — | — | — |
| Unilateral interstitial syndrome | 197 (42.5) | 106 (72.6) | 91 (28.6) | 72.6 (64.6–79.7.1) | 71.4 (66.1–76.3) | 71.8 (67.4–75.8) |
| Bilateral interstitial syndrome | 151 (32.5) | 97 (66.4) | 54 (17) | 66.4 (58.2–74) | 83 (78.4–87) | 77.8 (73.7–81.5) |
| Unilateral consolidation(s) | 87 (18.8) | 55 (37.7) | 32 (10.1) | 37.7 (29.8–46.1) | 89.9 (86.1–93) | 73.5 (69.2–77.5) |
| Bilateral consolidations | 57 (12.3) | 39 (26.7) | 18 (5.1) | 26.7 (19.7–34.7) | 94.3 (91.2–96.6) | 73.1 (68.8–77.1) |
| Unilateral pleural effusion | 156 (33.6) | 85 (58.2) | 71 (22.3) | 58.2 (48.8–66.3) | 77.7 (72.7–82.1) | 71.6 (67.2–75.6) |
| Bilateral pleural effusion | 52 (11.2) | 8 (5.5) | 44 (13.8) | 5.5 (2.4–10.5) | 86.2 (81.9–89.8) | 60.8 (56.2–65.2) |
| Any LUS sign present | 371 (80) | 131 (89.7) | 240 (75.5) | 89.7 (83.6–94.1) | 24.5 (19.9–29.6) | 45 (45.4–49.7) |
| CXR | 733 (%) | 187 (%) | 546 (%) | — | — | — |
| Monolateral consolidation(s) or ground glass opacity | 93 (12.7) | 41 (21.9) | 52 (9.5) | 21.9 (16.2–28.6) | 90.5 (87.7–92.8) | 73 (69.6–76.2) |
| Bilateral consolidations or ground glass opacity | 199 (27.1) | 77 (41.2) | 122 (22.3) | 41.2 (34.1–48.6) | 77.7 (73.9–81.1) | 68.3 (64.9–71.7) |
| Any CXR sign present | 290 (39.6) | 117 (62.6) | 173 (31.7) | 62.6 (55.2–69.5) | 68.3 (64.2–72.2) | 66.9 (63.3–70.3) |
Abbreviation: LUS, lung ultrasound.